



Outcomes of the adsorbed Sinovac-CoronaVac COVID-19 inactivated vaccine among the employee recipients in St. Luke's Medical Center Quezon City: an observational cohort study

Poster # 1266868



Almira V. Uy, MD
Ryan M. Llorin, MD
Deborah Ignacia D. Ona, MD

Mailing address:



References:




INTRODUCTION: The inactivated vaccine named CoronaVac, containing HB02 strain of SARS-CoV-2 created from Vero cells, created by the manufacturing company Sinovac was the first vaccine to arrive and be distributed in Manila, Philippines. It is important to determine the vaccine's effectiveness and safety among its recipients.

OBJECTIVE: The objective was to monitor the overall effectiveness of the inactivated COVID-19 vaccine on its recipients among the employees in the study hospital.


METHODS: This was an observational cohort study which included HCWs from SLMC who have received one and/or two doses of CoronaVac from March 2021. The primary outcome of the study was to determine the clinical effectiveness of the vaccine in reducing risk of COVID-19 infection. The secondary outcome was the vaccine safety endpoint.

RESULTS: Out of the 2954 CoronaVac vaccinees, a total of 368 HCWs have been infected with SARS-CoV-2. 146 (4.94%) recipients have been infected with COVID-19 after receiving their first dose, while 222 (7.51%) tested positive after the second dose. 179 recipients reported of adverse reactions following immunization, with majority of these HCWs experiencing minor symptoms. The relative risk for COVID-19 infection among those given was at 15.7%, suggesting the clinical effectiveness of the said vaccine. Receiving SINOVAC vaccine will reduce the risk of COVID-19 infection by 84.3%.

CONCLUSION: CoronaVac vaccine is clinically effective in reducing the risk and severity of COVID-19 infection among HCWs in the study institution. Likewise, this inactivated vaccine can be safely given to individuals who are eligible to receive COVID-19 vaccine.



Severity of COVID-19 among Sinovac-CoronaVac recipients



Documented symptoms of COVID-19 Sinovac-CoronaVac recipients

Sinovac-CoronaVac reduces risk of COVID-19 by 84.3%